In vitro synergistic activity of aztreonam (AZT) plus novel and old β-lactamase inhibitor combinations against metallo-β-lactamase-producing AZT-resistant Enterobacterales
- PMID: 34605763
- DOI: 10.1099/jmm.0.001427
In vitro synergistic activity of aztreonam (AZT) plus novel and old β-lactamase inhibitor combinations against metallo-β-lactamase-producing AZT-resistant Enterobacterales
Abstract
The emergence of metallo-β-lactamase (MBL)-producing Enterobacterales, mainly New Delhi metallo-β-lactamase (NDM), represents a clinical threat due to the limited therapeutic alternatives. Aztreonam (AZT) is stable to MBLs, but most MBL-producing Enterobacterales isolates usually co-harbour other β-lactamases that confer resistance to AZT and, consequently, its use is restricted in these isolates. We compared the ability of sulbactam (SUL), tazobactam (TAZ), clavulanic acid (CLA) and avibactam (AVI) to restore the AZT activity in MBL-producing AZT-resistant Enterobacterales isolates. A collection of 64 NDM-producing AZT-resistant Enterobacterales from five hospitals in Buenos Aires city, Argentina, were studied during the period July-December 2020. MICs were determined using the agar dilution method with Mueller-Hinton agar according to Clinical and Laboratory Standards Institute (CLSI) recommendations. AVI, SUL and TAZ were used at a fixed concentration of 4 mg l-1, whereas CLA was used at a fixed concentration of 2 mg l-1. A screening method based on disc diffusion to evaluate this synergy was also conducted. Detection of bla KPC, bla OXA, bla NDM, bla VIM, bla CTXM-1, bla PER-2 and bla CIT was performed by PCR. The AZT-AVI combination restored the AZT activity in 98.4 % of AZT-resistant strains, whereas CLA, TAZ and SUL did so in 70.3, 15.6 and 12.5 %, respectively, in isolates co-harbouring extended-spectrum β-lactamases, but were inactive in isolates harbouring AmpC-type enzymes and/or KPC. The synergy screening test showed an excellent negative predictive value to confirm the absence of synergy, but positive results should be confirmed by a quantitative method. The excellent in vitro performance of the AZT-CLA combination represents a much more economical alternative to AZT-AVI, which could be of use in the treatment of MBL-producing, AZT-resistant Enterobacterales.
Keywords: NDM; avibactam-aztreonam; clavulanic acid-aztreonam; monobactam; sulbactam; tazobactam.
Similar articles
-
Evaluation of gradient strip diffusion for susceptibility testing of aztreonam-avibactam in metallo-β-lactamase-producing Enterobacterales.J Clin Microbiol. 2024 Nov 13;62(11):e0064924. doi: 10.1128/jcm.00649-24. Epub 2024 Sep 30. J Clin Microbiol. 2024. PMID: 39345139 Free PMC article.
-
Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).J Chemother. 2023 May;35(3):198-204. doi: 10.1080/1120009X.2022.2090615. Epub 2022 Jun 22. J Chemother. 2023. PMID: 35731718
-
In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo-β-Lactamase-Producing Enterobacteriaceae.Microbiol Spectr. 2023 Jun 15;11(3):e0056923. doi: 10.1128/spectrum.00569-23. Epub 2023 May 8. Microbiol Spectr. 2023. PMID: 37154758 Free PMC article.
-
New β-Lactam-β-Lactamase Inhibitor Combinations.Clin Microbiol Rev. 2020 Nov 11;34(1):e00115-20. doi: 10.1128/CMR.00115-20. Print 2020 Dec 16. Clin Microbiol Rev. 2020. PMID: 33177185 Free PMC article. Review.
-
Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens.Pharmacotherapy. 2024 Dec;44(12):927-938. doi: 10.1002/phar.4629. Epub 2024 Nov 27. Pharmacotherapy. 2024. PMID: 39601336 Free PMC article. Review.
Cited by
-
Drug development concerning metallo-β-lactamases in gram-negative bacteria.Front Microbiol. 2022 Sep 15;13:959107. doi: 10.3389/fmicb.2022.959107. eCollection 2022. Front Microbiol. 2022. PMID: 36187949 Free PMC article. Review.
-
Pharmacokinetic/Pharmacodynamic Evaluation of Aztreonam/Amoxicillin/Clavulanate Combination against New Delhi Metallo-β-Lactamase and Serine-β-Lactamase Co-Producing Escherichia coli and Klebsiella pneumoniae.Pharmaceutics. 2023 Jan 11;15(1):251. doi: 10.3390/pharmaceutics15010251. Pharmaceutics. 2023. PMID: 36678879 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous